PLLA
Poly-L-lactic acid (PLLA) identifies a biodegradable polymer family. In aesthetic injectables, it does not identify one universal product or protocol. Sculptra and Lanluma both use PLLA, but their presentations, documentation, company relationships, and clinical contexts must be read separately.
At a glance
Section titled “At a glance”| Question | Practical answer |
|---|---|
| What is being injected? | Product-specific PLLA particles supplied in a presentation that requires preparation before use |
| Is it an immediate filler? | The injected fluid can create short-lived correction; the intended later tissue response develops gradually |
| Ready to use? | No. Preparation instructions are product- and market-specific |
| Initial products | Sculptra and Lanluma |
| Main caution | Shared PLLA does not establish shared reconstitution, placement, dose, treatment course, or duration |
What PLLA explains
Section titled “What PLLA explains”PLLA helps explain why these products are discussed as biodegradable particulate implants with a delayed tissue response rather than as conventional prefilled HA gels. Reviews describe gradual clinical change and a collagen-related response, while also showing variation in study design, treated anatomy, and protocol (systematic review in PMC 🔗).
PLLA alone does not tell an injector:
- how much diluent a product requires
- how long it should hydrate
- how it should be mixed or stored
- which plane or device is supported
- how much immediate correction to expect
- which anatomy is approved in a given market
- how long an individual result will last
Those are product-level questions.
Initial product map
Section titled “Initial product map”| Product | Supported identity | Presentation context | Company context |
|---|---|---|---|
| Sculptra | Injectable PLLA product | Regulator documentation lists PLLA with sodium carboxymethylcellulose and mannitol; current local instructions govern preparation | Galderma commercial brand context; FDA records identify the device and approval history |
| Lanluma | PLLA implant | Sinclair presents separate face/body product context and product-specific presentations | Sinclair commercial context; manufacturing and distribution roles require market-specific verification |
The original FDA-hosted Sculptra documentation identifies PLLA, sodium carboxymethylcellulose, and mannitol in the final composition (FDA device document 🔗). A later FDA supplement records updated labeling for Sculptra and Sculptra Aesthetic (FDA PMA record 🔗).
Sinclair identifies Lanluma as a PLLA implant and publishes product-specific indication and safety context rather than presenting it as a generic version of another PLLA product (Sinclair Lanluma 🔗).
Preparation is part of product identity
Section titled “Preparation is part of product identity”Reconstitution and hydration affect how a particulate PLLA product is handled. They should be documented from the current IFU or formal manufacturer material for the exact presentation and market.
Avoid carrying across:
- preparation volumes
- hydration intervals
- agitation methods
- anesthetic additions
- storage windows
- needle or cannula guidance
A protocol supported for one PLLA brand is not automatically transferable to another.
Immediate correction versus delayed response
Section titled “Immediate correction versus delayed response”The fluid present at treatment can temporarily change contour. That initial appearance should not be described as the final PLLA effect. The clinically relevant delayed response develops over time, and treatment-course reporting should identify whether it refers to a label, trial, consensus, or local practice.
This separation matters in consultation and follow-up: immediate post-treatment appearance, early resolution of fluid-related fullness, and later tissue change are different phases.
Safety interpretation
Section titled “Safety interpretation”PLLA safety discussions should distinguish:
- expected injection-site effects
- palpable but non-inflammatory nodules
- inflammatory nodules
- infection
- delayed foreign-body or granulomatous reactions
- vascular events
Technique, preparation, product placement, anatomy, and patient factors may all enter the interpretation. The evidence base for managing PLLA nodules remains heterogeneous; a scoping review maps that limitation rather than supporting one universal algorithm (PLLA nodule-management scoping review 🔗).
Related materials
Section titled “Related materials”- Nodules and delayed reactions provides a descriptive, product-aware assessment framework.
- Vascular and visual emergencies defines the time-critical activation and handover pathway.
- PLLA vs PDLLA separates polymer stereochemistry from finished-product formulation.
- PDLLA uses both D- and L-lactide-derived polymer structures and includes products with different particle architectures and hybrid compositions.
- CaHA is supplied as mineral microspheres in a gel carrier rather than as a reconstituted lactic-acid polymer product.
- PCL shows why even one polymer acronym can contain substantially different physical product forms.